IMC CS4

Drug Profile

IMC CS4

Alternative Names: Anti-CSF-1R-monoclonal-antibody-ImClone; IMCCS4; LY-3022855

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImClone Systems
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony-stimulating factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Breast cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 04 Oct 2017 Eli Lilly completes a phase I trial in Breast cancer and Prostate cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02265536)
  • 06 Jun 2017 Phase-I/II clinical trials in Malignant melanoma (Late-stage disease, Combination therapy, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT03101254)
  • 19 May 2017 Sidney Kimmel Comprehensive Cancer Center plans a phase I trial for Pancreatic cancer (Combination therapy) in USA (NCT03153410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top